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Introduction
In the search for new drugs to overcome drug-resistant 
infections and cancers, phytochemicals have become the 
go-to source for inspiration. In plants, isoprenoids serve 
as the backbone from which many phytochemicals are 
biosynthesised via the cytosolic mevalonate (MVA) and 
the 2C-methyl-D-erythritol-4-phosphate (MEP) path-
ways.1 Some phytochemicals, like flavonoids, are synthe-
sised via the phenylpropanoid pathway, they exhibit both 
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antimicrobial and anticancer activities.2 The antimicrobial 
activity could be a result of impairment of the cell mem-
brane integrity and cell agglutination.3 The anticancer 
activity could be due to modulation of various mecha-
nisms such as angiogenesis, apoptosis, metastasis, differ-
entiation and cell proliferation.4,5 The increase in research 
targeted at developing new drugs for cancer and infec-
tious diseases has gained momentum in the last decades.
Chrysin is a flavonoid predominantly present found in 
honey, blue passionflower and propolis.6 In vitro studies on 
chrysin and chrysin derivatives have demonstrated interest-
ing biological activity.7 Chrysin has shown potential anti-
cancer activities on several cancer cell lines including those 
derived from cancers of the prostate, pancreas, thyroid, 
glioblastoma, liver, cervical, nasopharyngeal, breast, lungs 
and haematological cancers.6,8 The mode of action of chry-
sin has been shown to be via apoptosis, cell proliferation 
and removal of inflammatory responses, suppression of 
NF-ĸB and angiogenesis.9–11 Antibacterial activity of flavo-
noids, including chrysin, has been reported against Gram-
positive and Gram-negative bacteria.12–16
7-O-Alkylchrysin derivatives have been explored for 
anticancer activity.17 Our group has extensive expertise in 
synthesising different flavonoid derivatives.18–20 In this 
paper, we explored the effect on the biological activity of 
different functional groups added on the position 7 in chry-
sin. To compare different moieties and carbon length 
chains, we synthesised both known and novel chrysin 
derivatives. 7-O-Bromochrysin and 7-O-alkylchrysin 
derivatives were explored employing green microwave 
processes in majority of the cases. The aim of this study 
was to investigate the antibacterial and anticancer activity 




Chrysin (shown in Figure 1) was used as the core flavone 
structure, modifications were undertaken at the 7-hydroxyl 
group using different methods. Different reaction solvents 
such as acetone, acetonitrile, dimethylformamide as well as 
different equivalents were used for addition of the linkers. 
Potassium carbonate (K2CO3) has been widely used in 
O-alkylation synthetic methods as a base reagent with the 
intention of producing a phenoxide anion on the chrysin 
scaffold.21 This nucleophile will then react with the electro-
philic R groups (Br-alkyl groups). Different equivalents 
were used with some reactions favouring 2 equiv. or 4 
equiv. to chrysin. Microwave chemistry has been at the 
front of green chemistry synthetic methods as it allows for 
reduction of solvent used, time and electricity as well as 
making some reactions more favourable.18 O-alkylation in 
chrysin is favoured on position 7, this is due to the interac-
tion between the carbonyl oxygen in position 4 and the 
hydroxyl in position 5.19 The proximity of these two groups 
allows the formation of hydrogen bonding which requires 
harsher conditions for O-alkylation. Steric hindrance also 
plays an important role, while the hydroxyl in position 7 is 
free to interact with bulky groups, only small groups would 
be possible to interact with the hydroxyl in position 5.22–24
We have explored all these conditions and synthetised 
a range of chrysin derivatives using stirring or micro-
wave techniques, selecting the ones that presented the 
highest yields. Compounds C1–C3 and C5–C7 were syn-
thesised through application of microwave-assisted 
O-alkylation in either acetone (method A) or acetonitrile 
(method C) (Scheme 1). Compounds C4 and C8 were 
synthesised through classical stirring O-alkylation as the 
microwave approach produced extremely low yields. The 
Mitsunobu reaction was also explored, using different 
conditions including sonication.25 However, these gave 
lower yields and purification problems. The use of a 
microwave reactor and less-hazardous reactants were 
aligned to a greener chemistry approach which was ben-
eficial for most of our compounds as it reduced the reac-
tion time from 12–24 h to just 0.2 h with a yield >45%. 
The microwave reactions were undertaken in 35-mL 
Pyrex pressure vessels, sealed with SP-D Pressure Caps 
both from CEM UK to which the reactants were added 
and suspended in a minimal volume. In the case of C4, 
tetra-n-butylammonium bromide was brought into the 
reaction, and this phase transfer catalyst has been widely 
used in single-phase microwave reactions to improve 
product yields by increasing the accessibility of the rea-
gents to the liquid phase, in this dimethylformamide.26 
Scheme 1 indicates the chrysin structure and the substitu-
ents employed for the O-alkylation.
7-O-alkylchrysin derivatives C1, C2, C4, C6, C7 and 
C8 were novel compounds. While C3 has been recently 
available commercially (Akos GmbH, Germany. Sigma-
Aldrich, UK. Mcule, USA), this compound has not been 
made available through the database Reaxys, so we present 
here its first characterisation.
Introduction of alkyl chains has the potential to form 
more lipophilic compounds, which could enhance the 
entrance of the compound into cells. This was explored for 
both carbon alkyl chains as well as halogen species opening 
up the possibility to form additional targets on further reac-
tion.27 Compound 3 has two nitro groups; nitro moieties 
have been a classic presence in drug design.28
A total of eight chrysin derivatives were synthesised and 
characterised. The structures of the products were confirmed 
Figure 1. Chrysin, showing the traditional numbering of 
positions.
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Scheme 1. General method for the synthesis of chrysin derivatives. Common numbering of protons on flavonoids is shown on 
chrysin structure. Carbon chains are numbered in the supplementary material. Yields presented in %: C1 (80), C2 (52), C3 (46), 
C4 (75), C5 (49), C6 (47), C7 (56) and C8 (94).
by 1H NMR, 13C NMR, IR and Mass Spectral data. All the 
compounds were taken for biological studies.
Antibacterial activity
In this study, we investigated the activity of the new deriva-
tives on Gram-negative bacteria (Escherichia coli, 
Pseudomonas aeruginosa, Pseudomonas fluorescens and 
Klebsiella pneumoniae) and Gram-positive bacteria 
(Staphylococcus aureus and Enterococcus). E. coli dwell 
mainly in the intestine of humans and animals; the patho-
genic strains can cause bloody diarrhoea23 vomiting and 
severe abdominal cramp. It is one of the major causes of 
food poisoning.29,30 The extended-spectrum β-lactamase 
(ESBL)-producing E. coli are of major importance due to 
their antibiotic resistance. ESBL are enzymes that confer 
antimicrobial resistance to most β-lactam antibiotics such 
as the monobactam aztreonam, cephalosporins and penicil-
lins.31 P. aeruginosa causes ventilator-associated pneumo-
nia and other nosocomial infections as well as sepsis 
syndrome.32,33 Recently, the World Health Organization 
(WHO) has identified P. aeruginosa as a priority pathogen 
due to the threat of extremely drug-resistant infections.34 P. 
fluorescens is rarely a cause of human disease; however, it 
might affect patients with a compromised immune system 
caused by cancer, cases have been reported of contami-
nated blood given through transfusions.35 This strain also 
produces antibiotics like mupirocin which are used in 
creams to treat skin MRSA-active infections.36 K. pneumo-
niae is present in the intestine, skin and mouth as a normal 
flora of these tissues, and it can damage the lungs (alveoli) 
if inhaled. They are resistant to most drugs,37 and it is the 
third microorganism commonly isolated in blood cultures 
of patients with sepsis.38 S. aureus is found on the skin, 
respiratory tract and nose, and is responsible for food poi-
soning, abscess, skin and soft tissue infections, wound and 
respiratory infections. It is also responsible for toxic shock 
syndrome, cellulitis, impetigo and boils.39,40 The introduc-
tion of penicillin reduced the high mortality but led to the 
development of β-lactamases which destroy penicillin. A 
semisynthetic penicillin analogue – methicillin was intro-
duced; however, S. aureus resistant to methicillin emerged 
rapidly (MRSA).41 Enterococcus is associated with nosoco-
mial infections as it rapidly acquires antibacterial resist-
ance.42 The Candida albicans fungus is a lifelong, harmless 
commensal member of the normal human microbiome. 
However, C. albicans can cause infections that range from 
superficial infections of the skin to life-threatening sys-
temic infections under certain circumstances.43 Several 
activities and factors have been identified which contrib-
utes to the pathogenic nature of this fungus. This includes 
biofilm formation, secretion of hydrolases, molecules 
which mediate invasion and adhesion to the host cells, phe-
notypic switching and thigmotropism.43 C. albicans can 
cause two major infections in humans: superficial infec-
tions and oral candidiasis and life-threatening systemic 
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infections which could spread into vital organs.44 C. albi-
cans (up to 75%) is present in the oral cavity and remains 
benign in normal humans but could cause recalcitrant oral 
cavity infection in immunocompromised individuals.43
Minimum Inhibitory Concentration (MIC) is defined 
as the lowest concentration of an ingredient that prevents 
visible growth of bacteria, used to evaluate the antimicro-
bial efficacy of compounds. As shown in Table 1, chrysin 
showed very weak antibacterial activity on the tested 
strains. This is in agreement with different studies, in 
where several flavonoids including chrysin, have shown 
modest studies.44 C5 and C6 did not demonstrate any anti-
bacterial activity on the tested strains. C2 and C8 showed 
weak activity on the strains, although they presented some 
selectivity for S. aureus. C4 was very weak antibacterial 
agents with either very low or no activity. Only C1 and C3 
showed activity on our tests. C1, although active on all 
the strains, clearly showed selectivity for S. aureus; while 
C3 was the most active one with activities closer to the 
ones demonstrated by the positive control on all the 
strains, specially on Gram-negative E. coli, and Gram-
positive S. aureus and Enterococcus faecalis. C1 and C3 
had the most polar groups in our family, with a carbonyl 
group (C1) and two nitro groups (C3), adding localised 
charges to the molecules. In respect to the parent com-
pound, C3 showed a 20-fold increase of activity on E. coli 
and E. faecalis, 16-fold increase on P. fluorescens and 
10-fold increase in activity on S. aureus; while C1 
achieved half of C3’s activity. Although the functional 
group NO2 has been indicated in many cases as toxic or 
prone to toxicity, several antibacterial and antifungal 
agents containing NO2 are currently available commer-
cially or in late phase of clinical trial, some examples 
include oxamniquine, nimorazole, OPC-67683 and fexi-
nidazole.45 While chrysin was not active on P. aeruginosa, 
MRSA and K. pneumoniae, compounds C1 and C3 
showed activity on these strains. It is interesting that the 
novel compound 3 was active on the number of strains 
especially difficult to treat strains such as MRSA, P. aer-
uginosa and K. pneumoniae.
Li et al.46 had previously synthesised chrysin deriva-
tives containing 3-carbon spacers attached to different 
positions. Their results on 7-OH derivatives showed they 
were the most effective with MIC values ranging from 
3.13 to 50 μg mL−1 against S. aureus and E. coli, respec-
tively. Another study using piperazine chrysin derivatives 
showed IC50 μg mL
−1 values in the range of 1.30 to 4 for 
S. aureus, 1.15 to 7 for E. Coli and 10 to >50 for P. aer-
uginosa.47 Only a handful of studies include chrysin or 
chrysin derivatives include investigation on MRSA, 
Alhadrami et al.48 reported MIC values of 15 and 
250 μg mL−1 for chrysin and hesperidin, a chrysin deriva-
tive, respectively. Similarly to the MRSA, flavonoids 
including chrysin have not been extensively studied on P. 
fluorescens; some reports related more to the food indus-
try and packaging have reported propolis presenting anti-
bacterial effect for P. aeruginosa and P. fluorensces.49 Zhu 
et al.50 reported the synthesis of several chrysin deriva-
tives with antimicrobial activity; results of MIC were in 
the range of 50 μg mL−1 for K. pneumoniae and 3 mg mL−1 
for C. albicans.
C1 and C3 demonstrated a potentially useful antifungal 
activity with MIC value range of 50 µg mL−1. These find-
ings are in agreement with our results. C5 and C6 did not 
present any antimicrobial activity.
Anticancer activity
The growth inhibition activities of this family of chrysin 
derivatives were determined in a series of tumour and non-
tumour cell lines. These cell lines represent some of the 
most common cancer types including leukaemia (myeloid 
K562 and lymphoid MOLT-4), colorectal (HCT-116 and 
Caco-2), breast (MCF-7 and MDA-MB 468), hepatocellu-
lar cancer (HepG2), lung cancer (A549), malignant meso-
thelioma (Mero-14), along with an immortalised normal 
bronchial epithelium cell line (BEAS-2B). BEAS-2B was 
used as a control to determine if the growth inhibition activ-
ity was specific to cancerous cell lines, an ideal anticancer 
agent would not be active on non-cancerous cells.
Table 1. Effect of chrysin derivatives on Escherichia coli, Pseudomonas aeruginosa, Klebsiella, Staphylococcus aureus, Enterococcus and 
Bacillus cereus following 72 h of drug treatment MIC is recorded in µg mL−1.
Compounds MIC in µg mL−1*
E. coli P. aeruginosa S. aureus MRSA 252 E. faecalis P. fluorescens K. pneumonia C. albicans
C1 50 100 25 100 50 62.5 125 50
C2 100 200 50 250 100 125 250 400
C3 12.5 25 12.5 62.5 12.5 31.3 62.5 50
C4 100 200 100 – – 125 250 100
C5–C7 – – – – – – – –
C8 100 – 50 125 100 – – 200
Chr 250 – 125 – 250 500 – 200
G 8 16 8 32 8 16 16  
F 125
MIC: Minimum Inhibitory Concentration; Chr: chrysin; G: gentamicin, this aminoglycoside has a wide range of antibacterial activity making it ideal as 
a positive control on activity tests;44,45 F: fluconazole, this antifungal agent is widely used to treat C. albicans infection presenting a variable range of 
MIC.46
No observed inhibition at MIC values ⩽250 µg mL−1.
*MIC values are expressed as a mean value ± SD from two independent experiments performed in triplicate.
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The results are shown in Table 2. Chrysin was very 
active in our studies with IC50 values ranging from 3 to 
50 µM, including the non-cancerous cell line BEAS-2B. On 
colorectal cancer model HCT-116, all compounds were 
relatively active, especially C1, C2 and C3 with similar 
activities on Caco-2, another colorectal cancer model. On 
breast cancer models MCF-7 and MDA-MB468, only C1, 
C2 and C3 showed activity; although chrysin, the parent 
compound, showed to be more active than its derivatives. 
On the hepatic cell line HepG2, majority of the compounds 
showed no activity although C1, C3 and C8 showed activ-
ity while chrysin was more active than them. MOLT-4 and 
K562 are models for potential antileukaemia activity. 
Chrysin showed the lowest IC50 values on these two cell 
lines and was therefore the most active flavonoid, although 
C1, C3 and C8 showed activity as well. C1, C2 and C3 had 
similar ranges of activity to chrysin on K562. A549 is a 
relevant model of lung cancer and Mero-14 has been 
employed as model for malignant mesothelioma especially 
in relation to asbestos.51,54 Chrysin was active on these two 
cell lines, with more affinity on A549 than Mero-14; in the 
case of A549, C8 demonstrated a reasonable activity while 
C1 and C3 were slightly weaker. On Mero-14, chrysin was 
not very active but C1, C3 and C8 showed activities with 
IC50 lower than 10 µM. BEAS-2B is a cell line derived from 
normal bronchial epithelia extracted during the autopsy of 
non-cancerous individuals.52,55 BEAS-2B can be used up to 
a certain degree to assess if a compound active on cancer 
cells is toxic to non-cancerous cells. Chrysin and C2 were 
moderately toxic with an IC50 ~50 µM, all the remaining 
compounds were either non-toxic on the cells or with low 
activity.
The results showed that chrysin was an active com-
pound, but it is also toxic to non-cancerous cells. From the 
derivatives, C1 and C3 were the most active across the 
spectrum of cell lines with weak activities on non-cancer-
ous cells. C5 and C6 showed preference for colon carcino-
mas. C5, C6 and C8 showed more selectivity for breast 
cancer model MDA-MB468 with C8 also showing activity 
on malignant mesothelioma Mero-14.
Although anticancer agents bearing a nitro moiety are 
generally considered toxic, some compounds with NO2 are 
currently being investigated, for example, misanidazole.56 
The fact that compound C3 showed lower toxicity to 
BEAS-2B, which makes it a promising candidate for future 
studies.
Chrysin alongside derivatives have been studied on our 
selection of cell lines. Chrysin has shown IC50 higher than 
200 µM on leukaemia cells lines including K562 and 
MOLT-3; MOLT-3 and MOLT-4 are cell lines originated 
from the same patient with T-cell acute lymphoblastic leu-
kaemia, having some differences in CD (cluster of differen-
tiation) expression and chromosomal rearrangement.57,58 
Samarghandian et al.59 reported IC50 values close to 20 µM 
for breast cancer cell line MCF-7 while similar value was 
reported by Androutsopoulos et al.60 for MDA-MB468. On 
a different study, Samarghandian et al.61 reported IC50 val-
ues in the order of 40 µM for chrysin on A549. Although 
chrysin has been tested for anticancer activity pathway elu-














































































































































































































































































































































































































































































































































































































































































































































































































































































6 Journal of Chemical Research 
reported quantifiable values.62 A study using Chinese and 
Brazilian propolis reported IC50 values higher than 50 µM 
for Caco-2 and 12–40 µM for HCT116, respectively.63 
Chrysin has also been investigated on hepatic model 
HepG2, with Zhang et al.64 reporting an IC50 value of 
98 µM. To the best of our knowledge, no studies using fla-
vonoids, propolis nor chrysin have been reported through 
the scientific literature, so we present here first ever studies 
of chrysin and its derivatives on this mesothelioma cell 
line.
Lipophilicity (clogP)
Lipophilicity has a significant impact on various drug prop-
erties including absorption, distribution and permeability.66 
For a drug to reach its target, needs to penetrate the lipid 
bilayer of the cellular membranes, and one of the first bar-
riers a drug encounters is situated in the enterocytes in the 
intestinal epithelia. In general, a rule of thumb indicates 
that lipophilic drugs have good absorption.67
Lipophilicity indicates partition between two immisci-
ble phases. In the case of enterocytes, the drug needs to be 
absorbed through the apical side, for this being a lipophilic 
molecule might be helpful; but once the drug is inside, it 
needs to travel through the cytoplasm to be able to exit 
through the basolateral side of the cell. In this situation, 
there needs to be a delicate equilibrium between lipophilic-
ity and lipophobicity, if the molecule is highly lipophilic, it 
might not be able to leave the lipid layer. One way of early 
detection during the drug design process is to employ the 
Lipinski’s Rule of Five, for which the calculated log10P is 
⩽5.68 Lipophilicity can be predicted using software, for 
example, ChemDraw, where a highly lipophilic drug would 
have a clogP >3.69 Highly lipophilic drugs would also have 
solubility problems. The clogP of several molecules in the 
market for oral delivery present clogP in the ranges of −1 to 
5, with the maximum between 1.5 and 3.70 In the case of 
antibacterial commercial drugs, it appears that general 
physicochemical properties for these compounds are out-
side the range of other types of pharmaceutical molecules. 
An in-depth analysis of marketed antibacterial molecules 
showed that for around 34.4% of them, their logP were in 
the range of 0–5.71
Chrysin has a clogP of 2.29 and is widely known to have 
absorption problems, therefore affecting its bioavailability, 
calculated to be 0.003%–0.02% through the oral route of 
administration.72,73 C1 has a clogP of 2.83, the ester group 
can enhance the lipid solubility of this molecule respect to 
chrysin, making it more available to cross the cellular bar-
rier. C3 has a clogP of 4.29, and the two nitro groups capa-
ble of ionisation can enhance the solubility of this 
compound. In the antimicrobial panel, only C1 and C3 
showed to be active; while compounds C2 and C4–C7 had 
clogP between 3.78 and 6.30, and they did not show any 
relevant antimicrobial activity. The halogenated compound 
C8 had a clogP of 4.26, but no interesting antimicrobial 
properties. In relation to anticancer activity, most of the 
compounds had clogP lower than 5 (except C2 and C5–
C7). C2 presented high anticancer activities in general but 
C5–C7 were quite inactive. The pKa for these derivatives 
were also predicted using ChemDraw 20.1, and they were 
in the range between 5.89 and 7.02 making them more of 
neutral molecules. It certainly emphasises than although 
lipophilicity is an extremely important property, other fea-
tures of the molecule are as relevant. From our group of 
compounds, C3 had a clogP ⩽5 and was the best biologi-
cally active molecule.
Conclusion
Chrysin is certainly a promising molecule for anticancer 
studies and can be an excellent scaffold for drug design as 
some derivatives offer incredible biological activities.50,74 
The synthetic procedures employed to produce the chrysin 
derivatives were designed and optimised to produce high 
yields of the novel compounds utilising greener chemistry 
conditions. In our microbiological studies, C1 and C3 
showed a remarkable increase of activity, but C3 when 
compared to chrysin, showed the most activity on all the 
strains especially ESBL E. coli, E. faecalis and S. aureus. 
This compound was also active on P. aeruginosa, MRSA, 
K. pneumoniae and the fungus C. albicans.
In our anticancer studies, we tested the compounds on a 
wide range of cancer models, like breast, hepatic, lung, leu-
kaemia, colon cancer and malignant mesothelioma as well 
as non-cancerous cells. While chrysin was very active on 
the cancer models, it also showed toxicity to non-cancerous 
cells, maybe due to lack of selectivity for any target. Again, 
C1 and C3 were the most active compounds with lower 
activity on non-cancerous cells with C3 being the most 
promising one.
Some antibiotics have been shown to also exert antican-
cer activity, so during early drug design it is important to 
assess new chemical entities for activity on both types of 
targets.75,76 The identification of the lead C3 through a 
greener synthetic method will permit the development of 
new agents against bacteria and cancer.
Experimental
Materials and instruments
Unless stated otherwise all chemicals and reagents were 
used as received. Synthetic reagents were purchased from 
Sigma-Aldrich, Thermo Fisher Scientific, Apollo Scientific 
or TCI-UK. 1H and 13C NMR spectra were measured on a 
Bruker Avance DPX 400 MHz spectrometer using DMSO-d6 
or CDCl3 as the solvent, and tetramethylsilane (TMS; δ = 0) 
as the internal reference. All solvents used for NMR analy-
sis were purchased from Cambridge Isotope Laboratories 
Incorporated. J-values are given in Hz. High-Resolution 
Mass Spectrometry for novel compounds were outsourced, 
and they were analysed using the positive electrospray ioni-
sation time-of-flight mass spectrometry (TOF MS ES) on 
Waters I-Class UPLC at Cambridge Analytical Services, 
University of Cambridge, UK. Calculated M + H were per-
formed using ChemDraw 20.1 software. Infrared spectra 
were measured on a Thermo Scientific Nicolet iS10 and 
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melting point analysis was performed on a Stuart Melting 
Point SMP20. Microwave-assisted reactions were per-
formed in a CEM Discover SP microwave reactor. Silica gel 
chromatography was performed using silica gel 60 Å with a 
pore size of 40–63 µm (Fluorochem Limited, Glossop, UK). 
Silica thin-layer chromatography was performed on pre-
coated aluminium sheets with a 0.2-mm thickness obtained 
from Thermo Fisher Scientific, UK. Anhydrous tetrahydro-
furan was distilled over sodium and benzophenone prior to 
use. All other anhydrous solvents were purchased from 
Thermo Fisher Scientific.
Method A, synthesis of C1, C2 and C3
Chrysin (0.12 g, 4.7 mmol) was added to a suspension of 
potassium carbonate (4.0 equiv., 0.52 g, 8.4 mmol) in ace-
tone (10.0 mL). 4-Bromobutyl acetate (2.0 equiv., 184 µL, 
9.4 mmol), 1-(bromomethyl)-3,5-dimethylbenzene (2.00 
equiv., 0.085 g, 6.4 mmol) or 1-bromo-2,4-dinitrobenzene 
(116.6 g, 4.7 mmol) were added to synthesise C1, C2 and 
C3, respectively, and the resulting suspension irradiated in 
a microwave reactor for 10 min at 120 °C, 900 W for C1 and 
C3 and 5 min at 80 °C, 900 W for C2. This was rapidly 
cooled by means of a vapour coolant to room temperature. 
This was then poured into crushed ice, leading to the for-
mation of a pale brown precipitate which was left at 4 °C 
for 24 h. After 24 h, the precipitate was filtered and washed 
with ice cold water, followed by petroleum ether, and eluted 
on silica gel using 2:1 ethyl acetate:petroleum ether, v/v. 
The solvent was evaporated, and the precipitate dried in an 
oven for 24 h at 50 °C to yield the desired product.
Method B, synthesis of C4
To a solution of chrysin (0.10 g, 0.40 mmol), potassium car-
bonate (0.79 mmol; 2.0 equiv.) and tetra-n-butylammonium 
bromide (0.2 equiv., 0.025 g, 0.08 mmol) in dimethylforma-
mide (10 mL) was added 1-bromo-2-methylpropane (2.0 
equiv., 84 μL, 0.99 mmol). The reaction was allowed to stir 
for 72 h at 50 °C. After 72 h, the mixture was diluted with 
ice cold water, acidified with HCl (6 N) and extracted with 
ethyl acetate. The organic layer was concentrated to yield a 
yellowish-brown solid which was chromatographed on sil-
ica gel using ethyl acetate: petroleum ether (20:80 to 100:0) 
as mobile phase.
Method C, synthesis of C5, C6 and C7
Potassium carbonate (2.00 equiv., 0.26 g, 4.2 mmol) was 
suspended in acetonitrile (10.0 mL) containing chrysin 
(0.12 g, 0.47 mmol). Two equiv. of bromoalkane (1-bro-
mooctane (142.6 μL, 9.4 mmol) for C5, 1-bromononane 
(195 μL, 9.45 mmol) for C6 or 1-bromodecane (235.3 μL, 
9.8 mmol) for C7) were added to a thick-walled microwave 
tube and the resulting suspension irradiated vigorously in a 
microwave reactor at 120 °C for 8 min at 900 W. The reac-
tion was cooled rapidly by means of an auto-installed 
cooler system to a temperature of about 30 °C and poured 
unto crushed ice. The precipitate formed was left at 4 °C for 
8–12 h after which the precipitate was washed with ice cold 
water, followed by petroleum ether and dried in an oven at 
50 °C for 12 h to yield the pure compounds.
Method D, synthesis of C8
Potassium carbonate (4.00 equiv., 0.52 g, 8.4 mmol) was 
suspended in acetonitrile (10.0 mL) and stirred in a micro-
wave tube for 30 min. Chrysin (0.12 g, 0.47 mmol) and 1 
equiv. of 1,4-dibromopentane (93 μL, 4.72 mmol) were 
added and the resulting suspension stirred for 24 h at 80 °C. 
The resulting suspension was allowed to cool to room tem-
perature and poured into crushed ice, leading to the forma-
tion of pale-yellow precipitate which was left at 4 °C for 
24 h. After 24 h, the precipitate was filtered and washed 
with ice cold water, followed by petroleum ether, and eluted 
in silica gel using 2:1 ethyl acetate:petroleum ether, v/v. 
The solvent was evaporated, and the precipitate dried in an 
oven for 24 h at 50 °C.
4-((5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)butyl acetate 
(C1). Yield: 80%; m.p. 122–124 °C; clogP: 2.83. 1H NMR 
(CDCl3, δ ppm) 1.83–1.94 (4H, m, 3"–H2 and 4"–H2), 2.09 
(3H, s, 8"–H3), 4.06 (2H, t, J = 4.4 Hz, 5"–H2), 4.24 (2H, t, 
J = 5.88 Hz, 2"–H2), 6.38 (1H, s, 6–H), 6.51 (1H, s, 8–H), 
6.69 (1H, s, 3–H), 7.55 (3H, m, 2'–H, 3'–H, 4'–H), 7.92 (2H, 
d J = 7.3, 2'–H, 6'–H), 12.9 (1H, s, 5-OH). 13C NMR (CDCl3, 
δ ppm) 20.9 (8"), 25.3 (3"), 25.6 (4"), 63.9 (5"), 67.9 (2"), 
76.7–77.3 (CDCl3), 93.1 (8), 98.5 (6), 105.73), 105.9 (4a), 
126.3 (3'/5'), 129.1 (4'), 131.3 (2'/6'), 131.8 (1'), 157.8 (8a), 
162.2 (5), 163.9 (2), 164.9 (7), 171.1 (7"), 182.4 (4). IR 
(cm−1): 1165.42 (C–O–C, large ring C–O stretch), 1031.25, 
1242.32 (C–O, phenolic), 1588.12 (C=C aromatic), 1605.21 
(C=O, ketone), 1751.27 (OC=O). HRMS (ESI) m/z: calcu-
lated for C21H20O6 [M + 1] = 369.1293, found 369.1330.
7-((3,5-dimethylbenzyl)oxy)-5-hydroxy-2-phenyl-4H-chromen-4-
one (C2). Yield: 52%; m.p.: 122–124 °C; clogP: 5.26. 1H 
NMR (CDCl3, δ ppm) 2.25 (6H, s, 9"–H3, 10"–H3), 4.95 
(2H, s, 4"–H2), 6.34 (1H, d, J = 2.4 Hz, 6–H), 6.48 (1H, d, 
J = 2.4 Hz, 8–H), 6.57 (1H, d, J = 2.7 Hz, 3–H), 6.92 (1H, s, 
6"–H), 6.97 (2H, s, 2"–H, 8"–H), 7.45 (3H, m, 3'–H, 4'–H, 
5'–H), 7.80 (2H, dd, J = 7.3, 2.6 Hz 2'–H, 6'–H), 12.80 (1H, 
s, 5-OH). 13C NMR (CDCl3, δ ppm) 23.3 (9"/10"),70.4–77.4 
(CDCl3), 93.5 (8), 100.9 (6), 105.9 (3), 105.9 (4a), 125.3 
(4"/8"), 126.3 (3'/5'), 129.1 (4'), 130.1 (2'/6'), 131.4 (1'), 
131.4 (6"), 135.5 (5"/7"), 136.4 (3"), 157.7 (8a), 162.2 (5), 
164.0 (2), 164.8 (7), 182.5 (4). IR (cm−1): 1158.49 (C–O–C, 
large ring C–O stretch), 1246.45 (C–O, phenolic), 1583.85 
(C=C aromatic), 1602.10 (C=O, ketone), 2854.31 (C–H, 
alkane), 3001.46 (C–H, aromatic). HRMS (ESI) m/z: calcu-
lated for C24H22O4 [M + 1] = 373.1395, found 373.1433.
7-(2,4-dinitrophenoxy)-5-hydroxy-3-phenyl-4H-chromen-4-one 
(C3). Yield: 46%; m.p. 292–294 °C; clogP: 4.29. 1H NMR 
(DMSO-d6, δ ppm) 6.71 (1H, D, J = 3.5 Hz, 6–H), 7.11 (1H, 
d, J = 3.5 Hz, 8–H), 7.19 (1H, s, 3–H), 7.65 (4H, m, 3'–H, 
4'–H, 5'–H, 3"–H), 8.12 (2H, d, J = 7.0 Hz, 2'–H, 6'–H), 8.57 
(1H, dd, J = 10.5, 3.5 Hz, 4"–H,), 8.98 (1H, d, J = 3.5 Hz, 
6"–H), 13.02 (1H, s, 5-OH). 13C NMR (DMSO-d6, δ ppm) 
30.7–40.4 (trace cyclohexane/acetone), 93.0 (8a), 102.1 
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(6), 105.3 (4a), 107.8 (3), 122.0 (6"), 122.5 (3"), 126.6 
(3'/5'), 129.2 (4'), 130.2 (2'/6'), 132.5 (1'), 140.7 (7"), 140.8 
(5"), 152.4 (1"), 157.1 (5), 160.4 (2"), 161.2 (7), 182.5 (4). 
IR (cm−1): 1149.55 (C–O–C, large ring C–O stretch), 
1248.32 (C–O, phenolic), 1535 (N=O, aromatic) 1593.47 
(C=C aromatic), 1623.80 (C=O, ketone). HRMS (ESI) m/z: 
calculated for C22H16N2O8 [M + 1] = 421.0627, found 
421.0661.
5-hydroxy -7- i sobutoxy -3-pheny l -4H-chromen-4-one 
(C4). Yield; 75%; m.p. 143–145 °C; clogP: 3.78. 1H NMR 
(CDCl3, δ ppm) 1.03 (6H, d, J = 6 Hz, 4"–H3, 5"–H3), 1.60 
(trace water), 2.12 (1H, m, 3"–H), 3.83 (2H, d, J = 6 Hz, 2"–
H2), 6.36 (1H, s, 6–H), 6.52 (1H, s, 8–H), 6.68 (1H, s, 3–H), 
7.55(3H, d, J = 8.4 Hz, 3'–H, 4'–H, 5'–H), 7.91 (2H, d, 
J = 12 Hz, 2'–H, 6'–H), 12.78 (1H, s, 5-OH). 13C NMR 
(CDCl3, δ ppm) 19.2 (4"/5"), 28.1 (2"/3"), 74.9–77.3 
(CDCl3), 93.1 (8), 98.7 (6), 105.6 (4a), 105.9 (3), 126.3 
(3'/5'), 129.1 (4'), 131.4 (2'/6'), 131.8 (1'), 157.8 (8a), 162.1 
(5), 163.9 (2), 165.3 (7), 182.5 (4). IR (cm−1): 1149.55 (C–
O–C, large ring C–O stretch), 123.99 cm−1 (C–O, phenolic), 
1587.00 (C=C aromatic), 1614.79 (C=O, ketone), 2859.02 
(C–H, alkane), 2953.21 (CH3, alkane), 3076.84 (CH, 
aromatic). HRMS (ESI) m/z: calculated for C19H18O4 
[M + 1] = 311.1239, found 311.1278.
5-hydroxy-7- (octy loxy) -3-pheny l -4H-chromen-4-one 
(C5). Yield: 49.3%; m.p. 77–80 °C; clogP: 5.47. 1H NMR 
(CDCl3, δ ppm) 0.92 (3H, t, J = 7.0 Hz, 9"–H3), 1.35 (8H, 
m, 5"–H2, 6"–H2, 7"–H2, 8"–H2), 1.48 (2H, m, 4"–H2), 1.49 
(2H, m, 4"–H2) 1.85 (2H, quint, J = 7.0 Hz, 3"–H2), 4.03 
(2H, t, J = 7.2 Hz, 2"–H2), 6.47 (1H, d, J = 4.0 Hz, 6–H), 
6.52 (1H, d, J = 4.0 Hz, 8–H), 6.68 (1H, s, 3–H), 7.27 
(CDCl3) 7.55 (3H, d, J = 11 Hz, 3'–H, 4'–H, 5'–H), 7.91 (2H, 
d, J = 9 Hz, 2'–H, 6'–H), 12.9 (1H, s, 5-OH). 13C NMR 
(CDCl3, δ ppm) 14.1 (9"), 22.7 (8"), 25.9 (7"), 28.9 (6"), 
29.2 (4"/5"), 29.3 (3"), 31.8 (2"), 68.7 (1"), 76.7–77.4 
(CDCl3), 93.1 (8), 98.6 (6), 105.6 (4a), 105.8 (3), 126.2 
(3'/5'), 129.1 (4'), 131.4 (2'/6"), 131.8 (1'), 157.8 (8a), 162.2 
(5), 163.9 (2), 165.2 (7), 182.5 (4). IR (cm−1): 1169.51 (C–
O–C, large ring C–O stretch), 1272.96 (C–O, phenolic), 
1587.89 (C=C aromatic), 1607.79 (C=O, ketone), 2643.39 
(C–H, alkane), 2918.76 (C–H, alkane), 3023.26 (C–H, aro-
matic). HRMS (ESI) m/z: calculated for C23H26O4 
[M + 1] = 367.1865, found 367.1899.
5-hydroxy-7-(nony loxy) -3-pheny l -4H-chromen-4-one 
(C6). Yield: 47%; m.p. 73–76 °C; clogP: 5.88. 1H NMR 
(CDCl3, δ ppm) 0.92 (3H, t, J = 7.0 Hz, 10"–H3), 1.32 (10H, 
m, 5"–H2, 6"–H2, 7"–H2, 8"–H2, 9"–H2), 1.48 (2H, m, 
4"–H2), 1.85 (2H, quint, J = 6.4 Hz, 3"–H2), 4.03 (2H, t, 
J = 7.6 Hz, 2"–H2), 6.37 (1H, s, 3–H), 6.50 (1H, s, 8–H), 
6.68 (1H, s, 3–H), 7.28 (CDCl3) 7.55 (3H, m, 3'–H, 4'–H, 
5'–H), 7.90 (2H, d, J = 13 Hz, 2'–H, 6'–H), 12.71 (1H, s, 
5-OH). 13C NMR (CDCl3, δ ppm) 14.1 (10"), 25.7 (9"), 
25.9 (8"), 28.9 (7"), 29.3 (6"), 29.3 (4"/5"), 29.5 (3"), 31.9 
(2"), 68.7 (1"), 76.7–77.3 (CDCl3), 93.1 (8), 98.6 (6), 
105.6 (4a), 105.9 (3), 126.3 (3'/5'), 129.1 (4'), 131.4 (2'/6'), 
131.8 (1'), 157.8 (8a), 162.1 (5), 163.9 (2), 165.2 (7), 182.5 
(4). IR (cm−1): 1169.51 (C–O–C, large ring C–O stretch), 
1272.96 (C–O, phenolic), 1505.20 (C=C aromatic), 
1660.79 (C=O, ketone), 2323.48 (C–H, alkane), 2643.39 
(C–H, alkane), 2918.76 (CH, alkane), 3018.56 (C–H, 
aromatic). HRMS (ESI) m/z: calculated for C24H28O4 
[M + 1] = 381.2021, found 381.2057.
7-(decy loxy) -5-hydroxy-3-pheny l -4H-chromen-4-one 
(C7). Yield: 56%; m.p. 74–76 °C; clogP: 6.30. 1H NMR 
(CDCl3, δ ppm) 0.89 (3H, t, J = 4.9 Hz, 11"–H3), 1.32 (12H, 
m, 5"–H2 6"–H2, 7"–H2, 8"–H2, 9"–H2, 10"–H2), 1.48 (2H, 
m, 4"–H2), 1.85 (2H, quint, J = 7.4 Hz, 3"–H2), 4.06 (2H, t, 
J = 7.4 Hz, 2"–H2), 6.38 (1H, s, 6–H), 6.52 (1H, s, 8–H), 
6.78 (1H, s, 3–H), 7.52 (3H, m, 3'–H, 4'–H, 5'–H), 7.90 
(2H, d, J = 7.8 Hz, 2'–H, 6'–H), 12.75 (1H, s, 5-OH). 13C 
NMR (CDCl3, δ ppm) 14.1 (11"), 22.7 (10"), 25.9 (9"), 
28.9 (8"), 29.3 (7"/6"), 29. 6 (4"/5"), 31.9 (3"), 68.7 (2"), 
76.7–77.4 (CDCl3), 93.1 (8), 98.6 (6), 105.6 (4a), 105.9 
(3), 126.3 (3'/5'), 129.1 (4'), 131.4 (2'/6'), 131.8 (1'), 157.8 
(8a), 162.1 (5), 163.9 (2), 165.2 (7), 182.5 (4). IR (cm−1): 
1169.51 (C–O–C, large ring C–O stretch), 1283.27 (C–O, 
phenolic), 1512.15 (C=C aromatic), 1663.49 (C=O, 
ketone), 2286.36 (C–H, alkane), 2323.33 (C–H, alkane), 
2645.76 (C–H, alkane), 3014.51 (C–H, aromatic). HRMS 
(ESI) m/z: calculated for C25H30O4 [M + 1] = 395.2178, 
found 395.2208.
7-((4-bromopentyl)oxy)-5-hydroxy-3-phenyl-4H-chromen-4-
one or 7-O-2-bromopentylchrysin (C8). Yield: 94%; m.p. 
123–124 °C; clogP: 4.26. 1H NMR (CDCl3, δ ppm) 1.42 
(trace cyclohexane), 1.62 (trace water),1.78 (3H, d, 
J = 9.6 Hz, 6"–H3), 2.08 (4H, m, 3"–H2, 4"–H2), 4.08 (2H, t, 
J = 4.8 Hz, 2"–H2), 4.22 (1H, s, 5"–H), 6.38 (1H, s, 6–H), 
6.53 (1H, s, 8–H), 6.69 (1H, s, 3–H), 7.28 (CDCl3), 7.55 
(3H, m, 3'–H, 4'–H, 5'–H), 7.91 (2H, d, J = 8.1 Hz, 2'–H, 
6'–H), 12.80 (1H, s, 5-OH). 13C NMR (CDCl3, δ ppm) 26.6 
(6"), 27.4 (3"), 37.3 (4"), 50.7 (5"), 67.7 (2"), 76.8–79.4 
(CDCl3), 93.9 (8), 98.6 (6), 105.7 (4a), 108.9 (3), 126.3 
(3'/5'), 130.1 (4'), 131.1 (2'/6'), 131.8 (1'), 157.6 (8a), 162.2 
(5), 163.8 (2), 164.9 (7), 182.5 (4). IR (cm−1): 765.53 (C–
Br), 1172.08 cm−1 (C–O–C, large ring C–O stretch), 
1101.61 and 1270.95 cm−1 (C–O, phenolic), 1603.28 cm−1 
(C=C aromatic), 1621.23 cm−1 (C=O, ketone), 2854.31 cm−1 
(C–H, alkane), 2943.23 cm−1 (C–H, alkane), 2965.54 cm−1 
(C–H, alkane), 3068.12 cm−1 (C–H, aromatic). HRMS 
(ESI) m/z: calculated for C20H19BrO4 [M + 1] = 405.0534, 
found 405.0521.
Cell culture and growth inhibition studies
DMEM supplemented with 10% heat inactivated FBS, 
l-glutamine (1.0 mM) and streptomycin (1.0 mM) was used 
to culture MCF-7 and Mero-14 cell lines. DMEM supple-
mented with 20% heat inactivated FBS, l-glutamine 
(1.0 mM) and streptomycin (1.0 mM) was used to culture 
Caco-2 cell line. RPMI-1640 supplemented with 10% heat 
inactivated FBS, l-glutamine (1.0 mM) and streptomycin 
(1.0 mM) was used to culture K652, HepG2, MDA-MB 
468, A549 and MOLT-4 cell lines. McCoys 5A supple-
mented with 10% heat inactivated FBS, l-glutamine 
(1.0 mM) and streptomycin (1.0 mM) was used to culture 
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the HCT-116 cell line. Bronchial Epithelial Basal Medium 
(BEBM) from Lonza was used to culture the HCT-116 cell 
line. Culture was undertaken in a humidified incubator with 
5% CO2 at 37 °C until 75% confluence was reached. The 
general method undertaken for growth inhibition studies 
used cells grown in T-75 cell culture flasks before being ali-
quoted into sterile 96-well plates and incubated for 12 h. The 
cells were then treated with a concentration gradient (200–
0 µM) of compounds for 72 h. Following this, the cells were 
aspirated and 30.0 µL of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) (5.0 mg mL−1 in 
PBS) were added. The plate was incubated for 3.5 h at 37 °C 
in an environment of 5% CO2 before the wells were aspi-
rated and 100 µL of DMSO added. The 96-well plates were 
agitated using an orbital stirrer for 60 s before absorbance 
readings at 570 and 630 nm were taken using a Thermo 
Labsystems MultiSkan Ascent system. For suspension cell 
lines, the same method was undertaken; however, MTS was 
used in place of MTT, following the manufacturer’s guide-
lines (Promega, UK). The growth inhibition studies using 
MTT/MTS assays were performed on a Thermo Labsystems 
MultiSkan Ascent system.
Bacterial and fungal growth and growth 
inhibition studies
Nutrient agar (agar, 15 g L−1, meat extract, 1 g L−1, peptone, 
5 g L−1, sodium chloride, 5 g L−1, yeast extract, 2 g L−1) was 
used to culture Bacillus cereus ATCC 10876, S. aureus 
ATCC 25923, Enterococcus faecalis NCIMB 13280, P. aer-
uginosa NCTC 13437, P. fluorescens ATCC 13525, Extended 
Spectrum Beta-Lactamase (ESBL) producing E. Coli NCTC 
13353, MRSA 252 and K. pneumoniae ATCC 13439, and 
Sabouraud Dextrose Agar (SDA) was used to culture C. albi-
cans MTCC227. Strains were cultured overnight (22–25 h) 
at 37 °C on nutrient broth for the preparation of cell suspen-
sions. Suspensions of bacterial cells (dissolved in PBS) were 
homogenised such that the spectrophotometry standard of 
5 × 105 CFU mL−1 (0.5 McFarland standards) was obtained.
Minimum inhibitory concentration studies
MIC is considered the concentration of sample that prevents 
a colour change of the media and inhibited bacterial growth 
completely. All samples were dissolved in Mueller Hinton 
Broth (MHB)/DMSO with a DMSO final concentration of 
2.5%. The resulting solution was added to MHB. Inoculum 
prepared in appropriate broth – MHB (100 µL) was then 
added. These plates were sealed and agitated using a plate 
shaker incubated for 18 h at 37 °C. A negative control (wells 
containing broth, DMSO and 100 µL of inoculum) was also 
prepared. Gentamicin was used as the reference antibiotic 
for the bacterial strains while fluconazole was the antifungal 
agents tested on C. albicans. The p-iodonitrotetrazolium 
chloride (INT) colorimetric assay was used to determine 
MIC. The assay measures the production of NADH. In order 
to determine MIC, 40 μL of 0.2 mg mL−1 of INT were added 
after incubation for 18 h at 37 °C and samples were screened 
for colour change from violet to red.
cLogP calculation
Calculated logP values were predicted using ChemDraw 
20.1.
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